Description

Simple

A medication used to stop bleeding in certain patients with genetic disorders leading to the body's inability to form normal blood clots.

Clinical

A hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Overview

Fibrinogen concentrate (human) is a hematological agent. It works by replacing a certain protein in the blood that helps with blood clotting. Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. It is a physiological substrate for three enzymes: plasmin, factor XIIIa and thrombin. It is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Pharmacology

Indication

For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Pharmacodynamic

Fibrinogen replaces the missing, or low coagulation factor.

Mechanism of action

Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin. During the... Read more

Absorption

Cmax is 140 mg/dL

Protein binding

Information currently not available.

Volume of distribution

Mean volume of distribution is 52.7 mL/kg.

Clearance

0.59 mL/h/kg

Half life

78.7 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Fibrinogen human
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with (R)-warfarin.
(S)-Warfarin
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with (S)-Warfarin.
4-hydroxycoumarin
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with 4-hydroxycoumarin.
Abciximab
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Abciximab.
Acenocoumarol
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Acenocoumarol.
Acetylsalicylic acid
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Acetylsalicylic acid.
Alpha-1-proteinase inhibitor
The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.
Alteplase
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Alteplase.
Amediplase
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Amediplase.
Aminocaproic acid
The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Fibrinogen human.
Aminomethylbenzoic acid
The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Aminomethylbenzoic acid.
Anagrelide
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Anagrelide.
Ancrod
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ancrod.
Anistreplase
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Anistreplase.
Antithrombin Alfa
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin Alfa.
Antithrombin III human
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Antithrombin III human.
Apixaban
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Apixaban.
Aprotinin
The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Aprotinin.
Ardeparin
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Ardeparin.
Argatroban
The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Argatroban.
1 References
  1. 1 . FDA label Link